» Authors » J Bolt-de Vries

J Bolt-de Vries

Explore the profile of J Bolt-de Vries including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 171
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mostert B, Sieuwerts A, Kraan J, Bolt-de Vries J, van der Spoel P, Van Galen A, et al.
Ann Oncol . 2014 Dec; 26(3):510-6. PMID: 25471333
Background: A circulating tumor cell (CTC) count is an established prognostic factor in metastatic breast cancer (MBC). Besides enumeration, CTC characterization promises to improve outcome prediction and treatment guidance. Having...
2.
Meijer-van Gelder M, Look M, Bolt-de Vries J, Peters H, Klijn J, Foekens J
Breast Cancer Res Treat . 2001 Dec; 68(3):249-60. PMID: 11727961
There is ample information on the clinical role of biologic factors in female breast cancer: urokinase-type plasminogen activator (uPA), its receptor uPAR, its inhibitors PAI-1 and PAI-2, cathepsin D and...
3.
de Witte J, Sweep C, Klijn J, Grebenschikov N, Peters H, Look M, et al.
Br J Cancer . 1999 Jul; 80(1-2):286-94. PMID: 10390010
The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since...
4.
Meijer-van Gelder M, Look M, Bolt-de Vries J, Peters H, Klijn J, Foekens J
J Clin Oncol . 1999 May; 17(5):1449-57. PMID: 10334530
Purpose: To evaluate whether cathepsin D, urokinase-type plasminogen activator (uPA), its inhibitor, plasminogen activator inhibitor-1 (PAI-1), or clinical factors can predict which patients are at risk for developing distant metastases...
5.
Foekens J, Look M, Bolt-de Vries J, Meijer-van Gelder M, van Putten W, Klijn J
Br J Cancer . 1999 Jan; 79(2):300-7. PMID: 9888472
There is controversy regarding the prognostic value of cathepsin-D in primary breast cancer. An increased level of cathepsin-D in tumour extracts has been found to be associated with a poor...
6.
Blok L, Bartlett J, Bolt-de Vries J, Themmen A, Brinkmann A, Weinbauer G, et al.
Int J Androl . 1992 Apr; 15(2):182-98. PMID: 1315310
Adult rats were treated with ethane dimethane sulphonate (EDS) to eliminate the Leydig cells. This treatment resulted in very low levels of testosterone in the blood and in the testis....
7.
de Jong F, Reuvers P, Bolt-de Vries J, Mulder E, Blom J, Schroeder F
J Steroid Biochem Mol Biol . 1992 Mar; 42(1):49-55. PMID: 1373073
Testosterone, 5 alpha-dihydrotestosterone and cyproterone acetate (CPA) were estimated in samples of prostate tissue, obtained from benign prostatic hyperplasia (BPH) patients who were or were not pretreated with CPA. Furthermore,...
8.
Block L, Bartlett J, Bolt-de Vries J, Themmen A, Brinkmann A, Weinbauer G, et al.
J Steroid Biochem Mol Biol . 1991 Jan; 40(1-3):343-7. PMID: 1659875
Adult rats were treated with ethane dimethane sulphonate (EDS), an agent that destroys Leydig cells. Within 5 days after EDS treatment, the levels of testosterone (T) in the circulation and...
9.
Veldscholte J, Bolt-de Vries J, van Rooij H, Trapman J, Mulder E
Biochim Biophys Acta . 1990 Apr; 1052(1):187-94. PMID: 2322591
Unlabelled: LNCaP tumor cells, derived from a metastatic lesion of a human prostatic carcinoma, are androgen-sensitive in cell culture. Although increase in growth rate is observed with low doses of...
10.
van Laar J, Bolt-de Vries J, Zegers N, Trapman J, Brinkmann A
Biochem Biophys Res Commun . 1990 Jan; 166(1):193-200. PMID: 2302201
Androgen receptor heterogeneity and phosphorylation were studied in the human LNCaP cell line. Fluorography after photoaffinity labeling as well as immunoblotting with a specific polyclonal antibody revealed that the human...